A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2013

Study Completion Date

February 28, 2015

Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BIOLOGICAL

REOLYSIN

1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.

DRUG

Gemcitabine

800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.

Trial Locations (2)

10467

Montefiore Medical Center, New York

78229

Cancer Therapy & Research Center at UTHSCSA, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Texas

OTHER

lead

Oncolytics Biotech

INDUSTRY